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A B S T R A C T
Malignant pleural mesothelioma (MPM) is an asbestos-related tumor arising in the pleural cavity. Symptoms reflect extension of disease and include shortness of
breath and chest pain. Unexplained pleural effusion and pleural pain in patients exposed to asbestos should raise the suspicion of MPM. The most common radiologic
presentation is ipsilateral pleural effusion with or without pleural thickening or a mass. Thoracoscopic biopsy remains the most appropriate procedure for definitive
diagnosis of mesothelioma. Despite advancement in diagnostic procedures and biomolecular research, this tumor nevertheless has poor prognosis. Mesothelioma
remains a diagnostic and therapeutic challenge and is likely to remain one in the years to come.
Here we present the first reported case of steroid treatment responsive pleural effusion in a 72 year-old-male that initially was misdiagnosed as rheumatoid related
effusion. However, Pleuroscopy with biopsy revealed mesothelioma.
1. Introduction
Malignant mesothelioma is a tumor arising from the mesothelial
cells or sub-mesothelial cells of the pleura, peritoneum or pericardium,
with more than 80% originate in the pleura [1]. The most common
cause of diffuse malignant mesothelioma in the United States is in-
halation of asbestos [2]. The latency from the time of exposure to the
development of malignant mesothelioma is several decades [3]. Low-
level exposures, as well as bystander are risk factors for the mesothe-
lioma. No threshold of asbestos exposure has been established for the
development of malignant mesothelioma [4]. Despite the fact that in-
dustrial use of asbestos was forbidden many years ago, new cases of
mesothelioma continue to appear because of the long latency of the
disease [5].
Here, we report a case of 72-years-old male with multiple admis-
sions for pleuritic chest pain associated with recurrent exudative
pleural effusions with dramatic response to steroids, initially mis-
diagnosed as connective tissue disease related pleural effusion. Yet it
was found to be mesothelioma.
2. Case presentation
Herein a 72-year-old male patient with no significant past medical
history apart from hyperlipidemia. He is a retired plumber and former
Veteran. He quit smoking 38 years ago. He presented to the Emergency
department (ED) with complain of worsening chest pain for few days
that increased with deep inspiration. Pain was piercing in nature
affecting his right side, sometimes associated with cough but no con-
comitant shortness of breath. His vital signs at that time were within
normal and his cardiopulmonary exam was unremarkable. Acute cor-
onary syndrome was ruled out through negative troponin series and a
normal EKG. Patient was diagnosed with pleurisy and was released
home from ED with a NSAID along with short steroid taper.
Two weeks later the patient presented again with the same com-
plain. Physical exam was unremarkable and initial laboratory results
were significant for mild leukocytosis. Chest x-ray showed new right
sided effusion with infiltrate versus consolidation (Fig. 1). Computed
tomography of the chest with intravenous contrast ruled out pulmonary
embolism yet it has showed a small right-sided pleural effusion as well
as right lower lobe infiltration versus consolidation. Patient also had
right hilar small lymphadenopathy on imaging and minimal pericardial
effusion (Figs. 2–4).
Patient then was admitted to the hospital and was treated as com-
munity acquired pneumonia with intravenous ceftriaxone and
Azithromycin. Patient was also started on intravenous methylpredni-
solone every six hours and ibuprofen as needed for pain control. The
white-cell count on subsequent days has increased from 14.5× 103 to
30.5×103/μL on day 3. Antibiotics were escalated to intravenous
vancomycin, Piperacillin and tazobactam. Pulmonary service was con-
sulted for worsening leukocytosis in setting of pneumonia and para-
pneumonic pleural effusion. At that time patient symptoms had im-
proved and there was no indication for aspiration because of minimal
effusion and subjective improvement. The pulmonologist has re-
commended repeat chest scan in 8–12 weeks to reassess adenopathy
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and confirm resolution. His white count was attributed to steroid ad-
ministration. He was discharged on oral antibiotics along with a pre-
dnisone taper upon improvement of his symptoms and labs.
Two weeks later the patient represented to ED with recurrence of his
symptoms few days after he had finished his steroid course. Physical
exam was significant for tachycardia 111 bpm and tachypnea, labora-
tory testing was Significant for leukocytosis of 19.6×103/μL. EKG
showed sinus tachycardia. Plain chest radiograph showed recurrence of
pleural effusion in the right side (Fig. 5a). Repeat Chest CT showed
worsening right pleural effusion along with progressive consolidative
changes in the right lower lobe (Figs. 5b, 6 and 7). Patient was admitted
and was started on intravenous vancomycin, Piperacillin, tazobactam as
well as methylprednisolone for presumed worsening pneumonia.
Echocardiogram demonstrated normal biventricular function.
Pulmonary service was re-consulted who did bedside ultrasound on
the next day showed very small right sided pleural effusion that is
unsafe to tap. The dramatic improvement of pleural fluid after steroid
treatment increased the suspicion of possible connective tissue disease
as a cause. Connective tissue diseases work-up was done, revealed po-
sitive rheumatoid factor along with strongly positive Anti-cyclic ci-
trullinated peptide (level > 70). Erythrocyte sedimentation rate C-re-
active protein were both elevated 61 mm/hr and 260.4, respectively.
ANA, ANCA profile and anti SCL-70 were negative. Before being dis-
charged the pleural effusion as resolved (Fig. 8). He was discharged on
prednisone 40 mg daily for two weeks until seen by pulmonary clinic
for follow up.
Patient stopped the treatment as a repeat x-ray done in his primary
care physician office after following up hospital visit showed complete
resolution of his effusion (Fig. 8b).
Few days later, patient was due for his pulmonary clinic follow up
and he complained of return of his pleurisy symptoms when he tapered
steroid. At that time, he was restarted on a prolonged steroid taper
starting at 60 mg of prednisone per day. Repeat chest scan for follow up
on the hilar lymphadenopathy showed near normalization of the size of
the lymph nodes and trace residual right pleural effusion (Fig. 8a and
b). Also, right lower lobe infiltrate showed resolution compared to prior
imaging. At that time the patient was still on steroid taper and was
asymptomatic (see Fig. 9).
One month later the patient was seen in the pulmonary clinic for
follow-up. Chest plain radiograph was normal and prednisone dose was
further reduced to 10 mg. Yet few days later the patient developed
pleuritic type chest pain and chest x ray showed re-accumulation of his
pleural effusion at the emergency department (Fig. 10).
Patient refused admission and Video-Consult to pulmonary was
done and patient was advised to restart on prednisone 40 mg until fu-
ture appointment in the pulmonary clinic for thoracentesis. Due to the
prolonged steroid course the patient was also started on Trimethoprim/
Sulfamethoxazole for prophylaxis against pneumocystis. And patient
returned to the pulmonary clinic one week later, and a repeat CXR
showed decreased pleural effusion responding to steroid (Fig. 11). At
that time, he was thought of as rheumatoid induced pleural effusion
steroid responsive, yet no tapping has been done.
About one month later (4 months since initial presentation) while
the patient was still taking 30 mg prednisone, his pleural effusion re-
curred, and first-time thoracentesis was done at the pulmonary clinic
with inconclusive fluid studies. Gram stain was negative and culture
later on had no growth. Patient was discharged on same treatment.
Patient developed atrial fibrillation with rapid ventricular rhythm
and was admitted through another facility and chest x ray still had
pleural effusion. Repeat thoracentesis results were exudative, Serum
protein 6.7 g/dl, Serum LDH 149 (87-241 IU/L), Fluid LDH 851 IU/L,
Fig. 1. Admission Plain radiograph with small pleural effusion.
Fig. 2. CT mediastinal view of the chest with lymphadenopathy.
Fig. 3. Pleural effusion on the right.
Fig. 4. Right lower lobe infiltrate.
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Negative microbiology, Fluid glucose 137 mg/dl, Fluid protein 3.2 g/dl,
WBC 206×103/μL (16 neutrophils, 12 monocytes, 60 lymphocytes),
Cytology results came back with atypical cells present on both thor-
acentesis. Patient again was readmitted for therapeutic and diagnostic
purposes from effusion recurrence. Third time thoracentesis done week
later was same on analysis. Patient was referred for pleuroscopy with
biopsy.
Pleuroscopy showed lots of loculations as well as adhesions. The
parietal pleural was infiltrated with what seemed to be inflammatory
tissue and had some areas of nodularity. Multiple biopsies were ob-
tained from the parietal pleura. The entire surface of the parietal pleura
including some of the diaphragmatic pleura was involved. Visceral
pleura was noted to be unaffected by gross exam. For his recurrent
pleural effusion, a Pleurx catheter was left for drainage and sympto-
matic relief.
Pathological exam report was positive for a tumor consistent with
mesothelioma (epithelioid type). Immunohistochemical stains per-
formed. Results were of cells positive for Calretinin, CK5/6, CK7, and
WT-1 but negative for Napsin-A, CK20, and TTF-1.
PET scan results revealed diffuse abnormal right pleural uptake
consistent with history of mesothelioma with no evidence of disease
elsewhere (Fig. 12).
Patient disease was classified as stage 1 as per the International
Union Against Cancer (UICC) and the American Joint Committee on
Cancer (AJCC) [6].Patient was referred to a specialized cancer center
for management.
3. Discussion
Despite the presence of some clinical and laboratory findings on
review of the case, these can be as misleading if not carefully assessed.
The differential diagnosis of this unexplained pleuropulmonary process
includes collagen vascular disease, thromboembolic disease, and ma-
lignant tumors. The recurrent effusion that occurred in the absence of
evidence of infection, as well as recurrent worsening chest pain that
was reported by the patient on admissions in lieu of dramatic response
to steroid on multiple occasions plus inability to do thoracentesis early
made the diagnosis of the case challenging.
Pneumonia can be a cause of exudative pleural effusions especially
if partially treated. Parapneumonic pleural effusion refers to pleural
effusion associated with bacterial pneumonia, a pulmonary abscess or
infected bronchiectasis [7]. This is less likely to be the case here since
the patient symptoms didn't fit with this diagnosis. Also, his very rapid
response to steroid treatment with marked regression of the effusion is
less likely to happen with a parapneumonic effusion.
Patients with collagen vascular disease can initially present with
recurrent pleural effusions [8]. Rheumatoid effusions are well described
in the literature with pleural involvement is the most common thoracic
manifestation of rheumatoid disease [9], yet the absolute incidence of
rheumatoid pleural effusion is low. Especially with the presence of anti-
rheumatoid factor and anti-Citrullinated peptide antibodies, rheuma-
toid disease is a high suspicion. Despite these suspicions the patient had
no history of a rheumatoid disease. Additionally, in rheumatoid in-
duced pleural effusion, one would see numerous polymorphonuclear
leukocytes at the time of presentation and as the effusion matures a
lymphocytic predominance can be appreciated [10]. Rheumatoid
Fig. 5. Worsening pleural effusion (a and b).
Fig. 6. Right middle lobe infiltrate.
Fig. 7. Worsening right lower lobe infiltrate.
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effusion is also characterized by low pleural fluid glucose level, usually
less than 30 mg/dl [11]. His pleural effusion analysis was atypical of
rheumatoid induced pleural effusion.
Malignant pleural effusion can result from primary malignancies of
the pleura or with intrathoracic and extra-thoracic malignancies that
reach the pleural space by hematogenous, lymphatic, or contiguous
spread [9]. Lung carcinoma is the most common cause of chest pain and
pleural effusions in this age group [8] These effusions are known as
paraneoplastic or paramalignant pleural effusions [9]. Malignant
mesothelioma is a tumor arising from the mesothelial cells or sub-me-
sothelial cells of the pleura, peritoneum or pericardium, with more than
80% originate in the pleura [1]. The most common radiographical
presentation is unilateral pleural effusion with or without ipsilateral
pleural thickening or mass [12]. Only a small number of patients are
asymptomatic at diagnosis, having an incidental detection of abnorm-
ality on imaging undertaken for a different reason [13]. Dyspnea is the
first symptom of pleural mesothelioma cases [14,15]. Pleural
Fig. 8. Dramatic improvement of right-side pleural effusion at hospital (a) and then at the clinic (b).
Fig. 9. CT scan showed regression of lymphadenopathy and near complete resolution of pleural effusion.
Fig. 10. Plain radiograph with recurrent moderate pleural effusion.
Fig. 11. Plain radiograph with decreasing right pleural effusion.
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mesothelioma can cause pain by irritating intercostal nerves or by in-
filtrating into the chest wall. Rarer manifestations include phrenic
nerve palsy, irritative cough, para-neoplastic phenomena, and sponta-
neous pneumothorax [16]. Malignant pleural effusion is often one of
the primary manifestation of mesothelioma and can be found in about
90% of patients at diagnosis [17]. Effusion sampling obtained by
thoracentesis and cytological examination is the most informative la-
boratory test for diagnosis. In patients who do not appear to have a
history of asbestos exposure, mesothelioma should not be ruled out if
other symptoms and signs of the disease are present. Unfortunately
establishing the diagnosis of mesothelioma can be difficult. In malig-
nant mesothelioma of the pleura, cytology displays a low sensitivity and
is not an accurate assay in differentiating malignant cells from reactive
mesothelial cells or lung cancer cells [18,19]. When nodular pleural
thickening is present, a fine-needle biopsy can be performed to establish
the diagnosis, but there is only a 25% chance that the biopsy will yield a
diagnosis in the presence of a no diagnostic effusion. Video-assisted
thoracoscopic surgery (VATS) is the diagnostic procedure of choice; it
yields a diagnosis in more than 90% of cases.
Upon careful review of literature and to the best of our knowledge,
we were unable to find any case report describing steroid responsive
pleural effusion secondary to mesothelioma.
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